A patient with CVID-enteropathy successfully treated with ustekinumab

Immunol Res. 2024 Dec 18;73(1):19. doi: 10.1007/s12026-024-09559-5.

Abstract

CVID (common variable immunodeficiency) is associated with a variety of gastrointestinal disorders including those mimicking Crohn's disease and ulcerative colitis. At present there is no clear trial data for the treatment of CVID enteropathy. There are no specific recommendations for treatment; however, it is commonly treated in a similar manner to inflammatory bowel disease, with corticosteroids, 5-aminosalicylates (5-ASA), azathioprine and anti-TNF therapy all being used. We describe the case of a 54-year-old with CVID-enteropathy presenting with diarrhoea and evidence of granulomatous inflammation on colonic biopsies. He was successfully treated with ustekinumab following failure/intolerance of prednisolone, 5-ASA and azathioprine. Features of CVID-enteropathy improved both clinically and histologically, with no evidence of serious treatment-related side effects.

Keywords: Absent plasma cells; CVID; Common variable immunodeficiency; Enteropathy; Granulomatous inflammation; Ustekinumab.

Publication types

  • Case Reports

MeSH terms

  • Biopsy
  • Common Variable Immunodeficiency* / complications
  • Common Variable Immunodeficiency* / diagnosis
  • Common Variable Immunodeficiency* / drug therapy
  • Humans
  • Male
  • Middle Aged
  • Treatment Outcome
  • Ustekinumab* / therapeutic use

Substances

  • Ustekinumab